BioSpace News Archive

Akumin Inc. held its annual general and special meeting of shareholders , May 14, 2020, on a virtual meeting platform.

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today reported that management’s discussion and analysis of financial condition and results of operations (“MD&A”) for the three months ended March 31, 2020 have been filed and can be viewed on the Company’s SEDAR profile at www.sedar.com.

A federal court has entered a temporary restraining order against Xephyr LLC, doing business as N-Ergetics, and three individuals associated with the entity, requiring them to immediately stop distributing colloidal silver products.

Align Technology, Inc. introduced the latest version of its proprietary ClinCheck treatment planning software at the Invisalign Scientific Symposium, a fully digital event for Invisalign-trained orthodontists.

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, releases the prepared remarks for the Q1 2020 conference call scheduled for May 14, 2020.

Willow Biosciences Inc. (“Willow” or the “Company”) (TSX: WLLW; OTCQB: CANSF) has released its financial and operating results for the three months ended March 31, 2020.

Balt announced today it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin The Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic Sub-Dural Hematoma.

The U.S. Food and Drug Administration continued to take action in the ongoing response effort to the COVID-19 pandemic

Enzychem Lifesciences, a clinical-stage biotherapeutics company engaged in the discovery and development of innovative medicines focused on the inflammation pathway, today announced that the Ministry of Food and Drug Safety (MFDS, formerly the Korea Food and Drug Administration), has accepted its Investigational New Drug (IND) application to initiate a Phase 2 study for its lead therapeutic candidate,

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 1,366,856 shares of the Company’s common stock, at a purchase price of $3.53 per share,